Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group

Autor: J, Thomas, B, de Pauw, A, Hagenbeek, R, Somers, P, Carde, U, Tirelli, N, Duez
Rok vydání: 1992
Předmět:
Zdroj: European journal of cancer (Oxford, England : 1990). (4-5)
ISSN: 0959-8049
Popis: Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.
Databáze: OpenAIRE